Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
|ClinicalTrials.gov Identifier: NCT00436800|
Recruitment Status : Completed
First Posted : February 19, 2007
Last Update Posted : September 18, 2009
To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.
To assess the toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms in the first line treatment of patients with metastatic or recurrent NPC.
|Condition or disease||Intervention/treatment||Phase|
|Nasopharyngeal Neoplasms||Drug: Gemcitabine Drug: Oxaliplatin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||41 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC)|
|Study Start Date :||March 2005|
|Primary Completion Date :||October 2008|
|Study Completion Date :||October 2008|
Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
1000mg/m² over 10mg/m²/minDrug: Oxaliplatin
100 mg/m² over 2 hours.
- Efficacy: Tumor response rate based on Response Evaluation Criteria in Solid Tumour (RECIST) criteria [ Time Frame: Baseline to end of study ]
- Safety: Clinical and laboratory criteria [ Time Frame: Baseline to end of study ]
- The incidence of adverse events based on National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 [ Time Frame: Baseline to 30 days post treatment ]
- Occurrence of serious adverse events (SAE) [ Time Frame: Baseline to 30 days post treatment ]
- Drop-out rate [ Time Frame: End of study ]
- Toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms. [ Time Frame: Baseline to end of study ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00436800
|Sanofi-Aventis Administrative Office|
|Hong Kong, Hong Kong|
|Study Director:||Iris Chan||Sanofi|